SVF
Level B· Emerging Clinical EvidenceClinical Trial

Intra-arterial renal infusion of autologous mesenchymal stem cells for treatment of chronic kidney disease in cats: Phase I clinical trial.

Thomson AL., Berent AC., Weisse C., Langston CE.

Clinical Trial on Chronic Kidney Disease, published in J Vet Intern Med (2019) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
J Vet Intern Med (2019)
Country
England
Reported sample size
—
PMID
30924554
DOI
10.1111/jvim.15486

Abstract (original English)

There are no known treatments that halt or reverse chronic kidney disease (CKD) in cats. In rodent models, stem cell treatment has been associated with improvement in renal function parameters, especially when stem cells were delivered intra-arterially to the kidney. To date, only IV and intrarenal stem cell infusions have been studied in cats with CKD with no clinically relevant improvement noted. To assess the safety and feasibility of intra-arterial delivery of autologous mesenchymal stem cells (MSC) in stromal vascular fraction (SVF) to the kidney in cats with CKD. Five client-owned domestic cats with International Renal Interest Society stage III CKD. Prospective cohort study (phase I clinical trial). Adipose tissue was harvested from study animals on day 0. On days 2 and 14, an infusion of MSC in SVF was administered into the renal artery via the femoral or carotid artery using fluoroscopic guidance. Serum creatinine and blood urea nitrogen concentration, plasma iohexol clearance, and quality of life assessments were monitored between days 0 and 90. The procedure was performed successfully in all cats. No severe adverse events were observed in any cat during the study period. Intra-arterial infusion of MSC into the renal artery in CKD cats was feasible and safe within a 3-month postoperative period. Efficacy and long-term safety have yet to be established. This procedure

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies exist, but sample sizes, methodology, or follow-up remain limited, so conclusions are not firm.

How we grade evidence
Adipose TissueAnimalsBlood Urea NitrogenCat DiseasesCatsCreatinineFemaleInfusions, Intra-ArterialKidney Function TestsMale
Systemic / IVChronic Kidney Disease
View on PubMedDOI

Related research